ZA201106419B - Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid - Google Patents
Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acidInfo
- Publication number
- ZA201106419B ZA201106419B ZA2011/06419A ZA201106419A ZA201106419B ZA 201106419 B ZA201106419 B ZA 201106419B ZA 2011/06419 A ZA2011/06419 A ZA 2011/06419A ZA 201106419 A ZA201106419 A ZA 201106419A ZA 201106419 B ZA201106419 B ZA 201106419B
- Authority
- ZA
- South Africa
- Prior art keywords
- barbituric acid
- composition
- brain delivery
- improved bioavailability
- diphenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
- C07D239/64—Salts of organic bases; Organic double compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60032704P | 2004-08-10 | 2004-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201106419B true ZA201106419B (en) | 2012-05-30 |
Family
ID=34942111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2011/06419A ZA201106419B (en) | 2004-08-10 | 2011-09-01 | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP1625848A1 (enExample) |
| JP (2) | JP2008509914A (enExample) |
| KR (2) | KR20070074549A (enExample) |
| CN (2) | CN102512422A (enExample) |
| AT (1) | ATE510541T1 (enExample) |
| AU (1) | AU2005280419B2 (enExample) |
| BR (1) | BRPI0513337A (enExample) |
| CA (1) | CA2576832C (enExample) |
| IL (1) | IL181247A (enExample) |
| MX (1) | MX2007001655A (enExample) |
| NZ (1) | NZ553653A (enExample) |
| SG (1) | SG163500A1 (enExample) |
| WO (1) | WO2006026095A2 (enExample) |
| ZA (1) | ZA201106419B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| US7683071B2 (en) | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| CN100502871C (zh) | 2002-12-11 | 2009-06-24 | 塔罗制药工业有限公司 | 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用 |
| EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
| CN102863579B (zh) * | 2012-09-14 | 2014-02-05 | 东南大学 | 一种巴比妥酸螯合树脂及其制备方法和应用 |
| KR102162003B1 (ko) | 2014-04-14 | 2020-10-06 | 삼성전자주식회사 | 무선 네트워크 연결 제어 방법 및 장치 |
| KR101822417B1 (ko) * | 2017-06-14 | 2018-01-29 | 주식회사 청도제약 | 인간의 체액에서 산화 스트레스를 측정하기 위한 방법 |
| GB202100352D0 (en) * | 2021-01-12 | 2021-02-24 | Balticgruppen Bio Ab | New methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2119701A (en) * | 1934-06-29 | 1938-06-07 | Winthrop Chem Co Inc | Alkoxyalkyl mercury nitrogen compounds |
| IL69722A (en) * | 1983-09-14 | 1986-09-30 | Taro Pharma Ind | Oxopyrimidine derivatives and pharmaceutical compositions containing them |
| DE4433764A1 (de) * | 1994-09-22 | 1996-03-28 | Asta Medica Ag | Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit |
| US6093820A (en) * | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
| US6756379B2 (en) * | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| EP1311270B1 (en) * | 2000-07-26 | 2008-01-09 | Taro Pharmaceutical Industries Limited | Non-sedating barbiturate compounds as neuroprotective agents |
| CN1896084A (zh) * | 2002-01-30 | 2007-01-17 | 塔罗制药工业有限公司 | 非镇静性巴比土酸衍生物 |
| CN100502871C (zh) * | 2002-12-11 | 2009-06-24 | 塔罗制药工业有限公司 | 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用 |
| EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
-
2005
- 2005-04-12 EP EP05290804A patent/EP1625848A1/en not_active Withdrawn
- 2005-08-10 SG SG201001644-2A patent/SG163500A1/en unknown
- 2005-08-10 EP EP05786192A patent/EP1781294B1/en not_active Expired - Lifetime
- 2005-08-10 NZ NZ553653A patent/NZ553653A/en not_active IP Right Cessation
- 2005-08-10 KR KR1020077005582A patent/KR20070074549A/ko not_active Abandoned
- 2005-08-10 BR BRPI0513337-8A patent/BRPI0513337A/pt not_active IP Right Cessation
- 2005-08-10 AU AU2005280419A patent/AU2005280419B2/en not_active Ceased
- 2005-08-10 MX MX2007001655A patent/MX2007001655A/es active IP Right Grant
- 2005-08-10 CN CN2011103358486A patent/CN102512422A/zh active Pending
- 2005-08-10 CA CA2576832A patent/CA2576832C/en not_active Expired - Fee Related
- 2005-08-10 WO PCT/US2005/028380 patent/WO2006026095A2/en not_active Ceased
- 2005-08-10 AT AT05786192T patent/ATE510541T1/de not_active IP Right Cessation
- 2005-08-10 KR KR1020127026918A patent/KR20120130256A/ko not_active Ceased
- 2005-08-10 CN CNA2005800340587A patent/CN101052403A/zh active Pending
- 2005-08-10 JP JP2007525753A patent/JP2008509914A/ja not_active Ceased
-
2007
- 2007-02-08 IL IL181247A patent/IL181247A/en not_active IP Right Cessation
-
2011
- 2011-09-01 ZA ZA2011/06419A patent/ZA201106419B/en unknown
-
2013
- 2013-06-04 JP JP2013118224A patent/JP2013177442A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2576832A1 (en) | 2006-03-09 |
| WO2006026095A2 (en) | 2006-03-09 |
| EP1781294A4 (en) | 2007-12-26 |
| SG163500A1 (en) | 2010-08-30 |
| NZ553653A (en) | 2010-06-25 |
| ATE510541T1 (de) | 2011-06-15 |
| HK1108313A1 (en) | 2008-05-02 |
| CN102512422A (zh) | 2012-06-27 |
| BRPI0513337A (pt) | 2008-05-06 |
| AU2005280419B2 (en) | 2010-09-23 |
| EP1781294B1 (en) | 2011-05-25 |
| EP1625848A1 (en) | 2006-02-15 |
| JP2013177442A (ja) | 2013-09-09 |
| MX2007001655A (es) | 2007-04-23 |
| IL181247A0 (en) | 2007-07-04 |
| JP2008509914A (ja) | 2008-04-03 |
| CA2576832C (en) | 2013-06-11 |
| KR20120130256A (ko) | 2012-11-29 |
| IL181247A (en) | 2012-05-31 |
| AU2005280419A1 (en) | 2006-03-09 |
| WO2006026095A3 (en) | 2007-02-01 |
| EP1781294A2 (en) | 2007-05-09 |
| KR20070074549A (ko) | 2007-07-12 |
| CN101052403A (zh) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201106419B (en) | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | |
| ZA200503656B (en) | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline | |
| MY134422A (en) | Platinum derivative pharmaceutical formulations. | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| WO2004004661A3 (en) | Boroproline compound combination therapy | |
| EP1619192A3 (en) | Aryl fused azapolycyclic compounds | |
| TW200504034A (en) | Therapeutic agents | |
| IL197890A (en) | Arylvinylchloroalkylan compounds and their preparation methods and uses | |
| TW200635903A (en) | Therapeutic agents | |
| SI1678172T1 (sl) | AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema | |
| PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
| IL162515A0 (en) | Substituted diketopiperazines as oxytocin antagonists | |
| SG178942A1 (en) | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same | |
| TW200509933A (en) | Therapeutic agents | |
| TW200633986A (en) | Therapeutic agents | |
| MXPA05011432A (es) | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. | |
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| WO2004035086A3 (en) | Method for treatment of demyelinating central nervous system disease using gm-csf | |
| TW200621788A (en) | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase Iε | |
| WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
| BRPI0410651A (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente | |
| AU2290902A (en) | Pharmaceutical compositions and methods for use | |
| MXPA05008990A (es) | Derivados de acido alcanoico sustituido con cicloalquilo, metodos para su produccion y su uso como medicamentos. | |
| AU8844301A (en) | Method for treating the central nervous system by administration of igf structural analogs |